I am disappointed with what we are seeing today and since all the Edgar posts; but I must say I can't be surprised.
I'm disappointed because I expected the S1 approvals/submittals to be followed by information. Here are the details of the plan. Maybe even some sort of update on the peptides?!
Did Joe speak to the peptide timeline on the NGIO call (that I missed and still can't read/listen to)? At this point, the timeline for the peptides has probably eclipsed the entire length of the timeline given for the total vaccine development in the first China deal. That says a lot, IMO.
But I can't say I'm surprised.
The approval of the S1s for GNBT were like an ice breaker in the winter Arctic. The path has been cleared. But we are still a ship without a motor. The current SP does not allow these (2) S1s to generate any power to move us forward. That is why I had hoped for the preferred shares S1 to be approved and interest in those shares to be proven. That would truly allow the business initiatives to get moving, as it wouldn't need a SP bump to provide capital.
As far as the NGIO S1s being submitted, that is certainly a hurdle cleared as well. But until they are approved, it does little for us. In fact, until we see some sort of information that shows a level of interest in shares of NGIO at a price that gets it listed, even the approval of the S1s may not do anything for us. We may be waiting until the first day of trading to see what the market interest is.
Of course, what can change all this is an announcement on a CV deal. And that relies on the peptide success. But since we haven't had ANY information on that for months, there is no evidence of success for new investors to hang their hats on.
And so we wait. And no one else is interested... for now.
Generex Biotechnology Corp. (GNBT) Stock Research Links